EU Panel Backs Drug for Rare Hereditary Angioedema EU Panel Backs Drug for Rare Hereditary Angioedema

Lanadelumab would be the first monoclonal antibody for preventing recurrent attacks of HAE in patients ages 12 years and older.International Approvals (Source: Medscape Medical News Headlines)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2R81rLU